TP53 and lung cancer: MiR-196b-5p activates the NF-κB signalling pathway in NSCLC, and generally, in lung cancer, miR-506 has been shown to directly target and suppress the NF-κB p65 subunit, leading to the production of ROS and triggering p53-mediated apoptosis [96,97].